Date: 2016-07-13
Type of information: Company acquisition
Acquired company: Biosafe Group (Switzerland)
Acquiring company: GE Healthcare (USA - WI)
Amount: undisclosed
Terms: * On July 13, 2016, GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions and services for our cell therapy customers, and expands GE’s technology reach to a number of new cell and therapy types. The cell therapy oncology market alone is expected to reach $30 billion by 20301 with more than 600 potentially life-changing therapies in clinical trials at the end of 2015. Olivier Waridel, Biosafe CEO, will continue to lead Biosafe within the new integrated GEHC structure.
Details: Biosafe, headquartered in the Lake Geneva region in Switzerland, with a global presence, has a 20 year track-record in automated cell processing and is a recognized leader in the field with reliable applications in bioprocessing, regenerative medicine and stem cell banking. Its proprietary products offer significant advantages over conventional processing tools, with closed fluid pathways, built-in traceability and single-use consumables. The strong strategic fit and complementary business models of GE Healthcare’s Life Sciences business and Biosafe combined with expanded capabilities in product development and commercial reach, will offer significant customer and ultimately patient benefits.
Related: Technology - Services Regenerative medicine
